Paradigm, formed in partnership with International Genomics Consortium, will help doctors tailor treatment

Newswise ANN ARBOR, Mich. and PHOENIX, Ariz. As a key step toward providing patients with treatments based on their own DNA profiles, the University of Michigan and the International Genomics Consortium (IGC) have launched a new joint venture that will help usher in an age of personalized medicine.

Called Paradigm, the new nonprofit company brings together the expertise of the U-M Health System and IGC, two leaders in using genetic information to understand and treat disease.

Beginning with cancer, and then extending into other disease groups, Paradigm will offer doctors and health care organizations anywhere access to whole gene and multi-gene sequencing and molecular diagnostics.

The company will also help support clinical trials at UMHS and other health systems.

Paradigm complements other DNA services offered by UMHS, including the MLabs reference laboratory, and the research-oriented DNA Sequencing Core. Paradigm is being formed under the Michigan Health Corporation, the part of UMHS that enables outside partnerships.

The company will be based in Ann Arbor, with additional operations at IGC headquarters in Phoenix.

Were thrilled to take this important step that allows us to harness the power of genetic information to guide patient therapy and improve outcomes, says Jay Hess, M.D. Ph.D., M.H.S.A., chair of the Department of Pathology at the U-M Medical School and a co-founder of Paradigm. IGC has a proven track record of bringing molecular diagnostics to market, yet shares our nonprofit patient-focused vision.

Paradigm builds on our ever-increasing understanding of the interplay of multiple disease-causing genes and how this affects sensitivity to specific treatment regimens, says Robert Penny, M.D., Ph.D., the chief executive officer and co-founder of Paradigm and IGC, which was formed by veteran genetic researchers and played a key role in compiling The Cancer Genome Atlas, a catalog of genes known to be involved in cancer. We will bring our expertise to bear to create true personalized medicine options for clinicians and their patients.

Initially, Paradigm will focus on offering services to oncologists and oncology groups, pathologists, academic medical centers and clinical trial groups studying personalized medicine regimens. Its first products will be especially of use in better tailoring treatments for cancer patients.

Read the original post:
Personalized Medicine: U-M Forms New DNA Diagnostics Joint Venture

Comments are closed.